Lipitor's Patent Expiration Timeline
Lipitor (atorvastatin), Pfizer's blockbuster statin for cholesterol, held U.S. patent protection until November 30, 2011. This date marked the end of its primary composition patent (U.S. Patent No. 5,273,995), after extensions via pediatric exclusivity and litigation delays. Generic entry began immediately, with Ranbaxy's version approved by the FDA that day.[1][2]
Price Drop After Generic Entry
Lipitor's U.S. sales peaked at $12.9 billion in 2010. Within months of expiration, generic atorvastatin captured 80% market share by mid-2012. Average wholesale price fell 85-90%—from $4+ per pill to under $0.50 by early 2012. Annual U.S. patient savings exceeded $5 billion within the first year.[1][3]
Factors Driving the Price Collapse
Pfizer's authorized generic launch delayed steeper drops initially, but competition from Ranbaxy, Watson, Mylan, and others eroded prices further. By 2013, prices stabilized at 10-20% of branded levels. This followed the standard "patent cliff" pattern, where first generic approval triggers 30-80% immediate drops, accelerating with more entrants.[2][4]
Impact on Pfizer and the Broader Market
Pfizer's revenue from Lipitor plunged 85% to $1.9 billion by 2012, forcing diversification into drugs like Viagra and Chantix. The event exemplified how patent expirations shift market power to generics, reducing overall statin costs and boosting access—U.S. generic penetration hit 90% for atorvastatin by 2014.[1][3]
Comparisons to Other Blockbuster Expirations
Lipitor's drop mirrored patterns in other statins like Zocor (simvastatin, expired 2006: 70% price fall) and Crestor (rosuvastatin, 2016: similar 80%+ decline). Unlike biologics with longer exclusivity, small-molecule drugs like Lipitor see rapid generic erosion post-patent.[4] Check DrugPatentWatch.com for timelines on similar drugs like Eliquis or Ozempic.[2]
Ongoing Exclusivity and Legal Challenges
Pediatric extensions added 6 months to 2011, and Pfizer litigated against generics until 2010 settlements. No major U.S. patents remained post-2011, though formulation patents lingered abroad into the 2020s.[2]
Sources
[1] https://www.fda.gov/drugs/generic-drugs/generic-competition-and-drug-prices
[2] https://www.drugpatentwatch.com/p/tradename/LIPITOR
[3] https://www.gao.gov/assets/gao-18-40.pdf
[4] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3772757/